10-K: Jupiter Neurosciences Faces Going Concern Doubt Amid Losses

Jupiter Neurosciences, a clinical-stage pharmaceutical company, reported significant net losses and negative cash flows for 2025, raising substantial doubt about its ability to continue as a going concern, despite launching a new consumer product line and advancing clinical trials.

Summary

• Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company focused on neuroinflammation treatments through its JOTROL resveratrol platform, primarily targeting Parkinson's Disease (Phase IIa clinical trial initiated in Q2 2026).
• The company launched a new strategic initiative in March 2025, introducing Nugevia, a consumer-oriented product line for longevity and wellness, with initial direct-to-consumer sales beginning in Q4 2025.
• Net revenues for the year ended December 31, 2025, were $21,796 from Nugevia product sales, compared to $0 in 2024.
• The company reported a net loss of $8,644,897 for 2025, significantly higher than the $2,439,625 net loss in 2024.
• Negative cash flow from operating activities increased to $5,413,736 in 2025 from $3,911,004 in 2024.
• As of December 31, 2025, the accumulated deficit reached $34,667,026, up from $26,022,129 in 2024.
• Management and the auditor have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Research and Development (R&D) expenses increased to $2,086,574 in 2025 from $492,660 in 2024, driven by consulting fees, payroll, stock-based compensation, and clinical trial supplies for the Parkinson's trial.
• General and Administrative (G&A) expenses rose by 163% to $6,839,712 in 2025 from $2,598,622 in 2024, mainly due to increased employee salaries, consulting, professional services, and investor relations.
• The company secured a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville) on October 24, 2025, allowing it to sell up to $20.0 million of common stock, and received $6.0 million in pre-paid advances via convertible promissory notes.
• Jupiter Neurosciences received gross proceeds of $11 million from a registered public offering in December 2024, listing its common stock on The Nasdaq Capital Market under the symbol JUNS.
• The company received notices from Nasdaq on February 26, 2026, for non-compliance with the minimum bid price ($1.00) and minimum market value of listed securities ($35 million) requirements, with a deadline of August 25, 2026, to regain compliance.
• Executive officers' salaries were significantly reduced from October 1, 2023, until December 4, 2024, when additional capital was raised, after which they were adjusted to 105% of their original base salaries.
• The company relies heavily on its exclusive worldwide license agreement with Aquanova AG for its JOTROL technology, which is critical for both its pharmaceutical and Nugevia product lines.
• Service agreements were entered into with Asian partners on June 3, 2024, for clinical development, regulatory affairs, and manufacturing guidance in Southeast Asia, paid for with an upfront issuance of 3,487,500 shares of common stock valued at $4,638,375.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial losses, negative cash flow, and the explicit 'going concern' warning from both management and the auditor. While there are positive developments in product launches and clinical trial progression, the severe financial distress and Nasdaq delisting risk overshadow these achievements, indicating high operational and investment risk.

Positives

• Successfully launched the Nugevia consumer product line in Q4 2025, generating initial revenues of $21,796.
• Initiated a Phase IIa clinical trial for Parkinson's Disease (JNS115) with final IND approval from the FDA in November 2025, expected to start in Q2 2026.
• JOTROL, the proprietary resveratrol formulation, demonstrated significantly improved bioavailability in a Phase I study, exceeding target CMax levels without severe adverse events.
• Secured a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20.0 million in equity, providing a potential source of future capital.
• Received $6.0 million in pre-paid advances via convertible promissory notes from Yorkville.
• Completed a registered public offering in December 2024, raising $11 million in gross proceeds and listing on The Nasdaq Capital Market.
• Established strategic service agreements with Asian partners to accelerate product development and potential out-licensing deals in Southeast Asia, leveraging local expertise.
• Obtained patent approvals for JOTROL in key markets including the USA, Japan, China, Hong Kong, and specific European countries, extending protection until 2036.
• The FDA accepted cross-referencing of Phase I data for the Parkinson's Phase IIa trial, potentially streamlining future development for other indications.
• The company has a strong intellectual property position for JOTROL, co-owning the patent with Aquanova and holding exclusive worldwide license rights.

Negatives

• Incurred significant net losses of $8,644,897 in 2025, a substantial increase from $2,439,625 in 2024.
• Experienced negative cash flow from operating activities of $5,413,736 in 2025, indicating ongoing cash burn.
• Accumulated deficit grew to $34,667,026 as of December 31, 2025, highlighting a history of unprofitability.
• Management and the auditor have raised substantial doubt about the company's ability to continue as a going concern.
• Received notices from Nasdaq on February 26, 2026, for non-compliance with minimum bid price and market value of listed securities requirements, risking delisting.
• The fees paid to Dominant Treasure Health Company Limited ($2,300,000) for strategic services in Asia are non-refundable and not tied to milestones or performance, posing a financial risk if services are not adequately performed.
• The shares issued to Asian Partners for services (3,487,500 shares with an aggregate fair value of $4,638,375) are not protected against non-performance, potentially leading to dilution without commensurate value.
• The company has not generated meaningful revenue from product sales to date, with Nugevia sales only starting in Q4 2025 and contributing a minimal $21,796.
• Substantial additional capital will be required to finance operations, and there is no assurance it can be raised on acceptable terms, potentially forcing delays or elimination of R&D programs.
• Raising additional capital may cause substantial dilution to stockholders or impose restrictive covenants.
• Low trading volume in common stock may limit the ability to draw on the Standby Equity Purchase Agreement.
• The company's substantial indebtedness ($6,000,000 principal as of Dec 31, 2025) may adversely affect cash flow and ability to meet debt obligations.
• The company has limited resources and is focusing efforts on JOTROL for specific indications, potentially missing other profitable opportunities.
• The company faces significant competition in both pharmaceutical and nutraceutical markets from larger, more resourced companies.
• The regulatory approval process for drug candidates is lengthy, expensive, and uncertain, with no guarantee of success.
• The company has identified material weaknesses in internal control over financial reporting due to inadequate segregation of duties and lack of a formal internal control environment.

Risks

• Substantial amount of indebtedness may adversely affect cash flow and ability to operate, comply with debt covenants, and make payments.
• Low trading volume in common stock may limit or prevent the ability to draw on the Standby Equity Purchase Agreement to pay down convertible promissory notes.
• Failure to generate meaningful revenue from product sales and expectation of continued significant net losses for the foreseeable future.
• Management's conclusion and auditor's explanatory paragraph regarding substantial doubt about the ability to continue as a going concern.
• Requirement for substantial additional capital to finance operations; inability to raise capital may force delays, reductions, or elimination of R&D programs or commercialization efforts.
• Raising additional capital may cause substantial dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Uncertainty regarding the actual number of common stock shares to be issued pursuant to the SEPA, potentially leading to substantial dilution.
• Significant dependence on the exclusive, worldwide license agreement with Aquanova; any adverse development could materially and adversely affect operations.
• Shares issued in advance to Asian Partners for services could have a material negative impact if services are not performed per agreements.
• Fees paid to Dominant Treasure Health Company Limited for strategic services in Asia are non-refundable and not tied to milestones or performance, posing a material negative impact if services are not performed.
• Limited resources and focus on particular JOTROL indications may lead to failure to capitalize on other potentially more profitable indications or product candidates.
• Significant competition from other companies developing and marketing technologies or products more rapidly, effectively, safely, or less expensively.
• Potential failure in efforts to develop the proprietary drug delivery platform, JOTROL, to build a pipeline of indications.
• FDA, EMA, or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• Difficulties from changes to current regulations and future legislation.
• High dependence on the ability to attract and retain highly skilled executive officers and employees.
• Failure to meet Nasdaq Capital Market continued listing requirements could result in delisting of securities.
• Price of common stock could be subject to rapid and substantial volatility, including short squeezes, lower trading volume, and less liquidity.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome; clinical trials may not demonstrate safety and efficacy or produce positive results.
• Product candidates may cause serious adverse events, toxicities, or other undesirable side effects, preventing regulatory approval or market acceptance.
• Delays or difficulties in patient enrollment and/or maintenance in clinical trials could delay or prevent regulatory submissions or approvals.
• Product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others.
• The patient population suffering from MPS I and MELAS syndrome is small and not precisely established; smaller actual patient numbers could adversely affect revenue and profitability.
• Product candidates may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
• Significant risk of product liability; inability to obtain sufficient insurance coverage could have an adverse effect.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; inability to obtain approval would substantially harm the business.
• Regulatory approval processes for rare diseases are uncertain due to lack of precedent and broad discretion of authorities.
• Even if product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
• Inability to obtain orphan drug designation or maintain orphan drug exclusivity, or exclusivity may not prevent competing products.
• Failure to obtain accelerated development designations could increase expense and delay marketing approvals.
• Nugevia nutritional supplement products may not have intended effects or cause undesirable side effects, harming the business.
• Competitors may develop nutritional supplement products that are less expensive, safer, or more appealing, diminishing Nugevia's commercial success.
• Nugevia products are subject to regulatory requirements; failure to comply could lead to significant penalties or claims.
• Information technology systems and those of partners are subject to cybersecurity threats and disruptions.
• Employees and executives may use artificial intelligence tools in ways that expose confidential information or intellectual property.
• Operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics, and other events beyond control.
• Risks associated with marketing product candidates internationally, including differing regulatory requirements, economic challenges, and compliance with foreign laws.
• Anti-takeover provisions in corporate documents and Delaware law could impair a takeover attempt.
• Fee-shifting provision in bylaws may discourage stockholders from pursuing actions against the company.
• Inability to protect intellectual property and proprietary technologies, including patents and trade secrets.
• Commercial success depends on operating without infringing third-party patents; claims of infringement may result in liability or delay efforts.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Inability to protect intellectual property rights throughout the world due to expense and differing legal protections.
• Dependence on third parties to conduct clinical trials; unsatisfactory performance may harm the business.
• Reliance on third-party manufacturers (Aquanova and Catalent) for JOTROL production; difficulties could delay or prevent supply.
• Reliance on third parties for Nugevia product line promotion and sales; failure to comply with regulations or ineffectiveness could adversely affect business.
• Reliance on third-party manufacturers and distributors for Nugevia product line; failure to perform could adversely affect business.
• Reliance on third parties may require sharing trade secrets, increasing risk of discovery or misappropriation.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, or incur debt/contingent liabilities.
• Inability to establish collaborations on commercially reasonable terms may alter development and commercialization plans.
• Products may not receive coverage and adequate reimbursement from third-party payers, harming the business.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Principal stockholders and management own a significant percentage of stock, exerting significant control.
• Common stock may be subject to penny stock rules in the future, making resale more difficult.
• If benefits of any proposed acquisition do not meet expectations, market price of common stock may decline.
• Changes in accounting principles or their interpretation could result in unfavorable charges or effects.
• Inability to maintain effective internal control over financial reporting could lead to loss of investor confidence.
• Auditor not required to attest to effectiveness of internal controls as an emerging growth company.
• Exemption from certain disclosure requirements as a smaller reporting company could make common stock less attractive.
• Significant increased costs and management time required for operating as a public company.
• Shares eligible for future sale may adversely affect the market price.

Future Outlook

The company expects to continue incurring significant net losses for the foreseeable future as it advances its JOTROL pharmaceutical pipeline through clinical development. Future capital needs are substantial and depend on the progress and costs of R&D, regulatory reviews, and commercialization efforts. The company aims to investigate other CNS indications like Mild Cognitive Impairment (MCI) and Alzheimer's disease following the Parkinson's study, and plans to submit a new grant application after Phase IIa Parkinson's results. International expansion for the Nugevia brand is planned for Europe, the Middle East, and Southeast Asia through regional partnerships. The company intends to apply its fee-shifting provision broadly to all actions except for claims brought under the Exchange Act and Securities Act.

Management Comments

• "Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern."
• "We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms."
• "We believe, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for potential therapeutic effects. Currently available resveratrol products cannot reach these levels without causing severe gastrointestinal side effects."
• "We believe the Phase I study we have conducted indicates that we have resolved the poor bioavailability issue with JOTROL."
• "Nugevia's launch is a pivotal move to monetize Jupiter's proprietary science, support ongoing clinical trials, and capture a share of the booming longevity market."
• "We believe that our core management team structure has proven experience in utilizing outside resources which allows us to efficiently execute several programs simultaneously in what we believe to be a very cost-effective way."
• "The Asian market is very large and hard to penetrate for a small company and we believe that our strategy with these agreements is cost effective and have the possibility to accelerate an out-licensing deal in the Southeast Asian territories."
• "We intend to apply the fee-shifting provision broadly to all actions except for claims brought under the Exchange Act and Securities Act."

Industry Context

StockSavvy.ai notes that Jupiter Neurosciences operates in two highly competitive and capital-intensive sectors: clinical-stage pharmaceuticals and the rapidly growing nutraceutical market. The focus on CNS disorders like Parkinson's and Alzheimer's places it against major pharmaceutical players with significantly greater resources, such as Eli Lilly and Eisai/Biogen, who have recently achieved FDA approvals for Alzheimer's treatments. The nutraceutical market, projected to reach $8 trillion by 2030, is also crowded with established brands like ChromaDex, Novos, and Nestle Health Science. Jupiter's differentiation hinges on its proprietary JOTROL technology for enhanced resveratrol bioavailability, which, if proven effective in clinical trials and successfully commercialized, could carve out a niche. However, the substantial financial losses and 'going concern' warning are significant red flags in an industry where sustained funding is critical for long-term success.

Comparison to Industry Standards

• In Parkinson's Disease, Jupiter's JOTROL is entering Phase IIa, while established treatments like levodopa/carbidopa have been standard since the 1960s. Newer therapies are emerging, but none have halted disease progression, indicating a high unmet need that JOTROL aims to address.
• For Alzheimer's Disease, Jupiter's JNS108 is in preclinical stages, with plans for a Phase II trial. This contrasts with recent FDA approvals for Biogen's Aduhelm (though withdrawn due to reimbursement issues) and Eli Lilly's donanemab ($32,000 annually), and Eisai/Biogen's Leqembi ($26,000 annually), which target amyloid-beta plaques. Jupiter's approach with resveratrol focuses on oxidative stress and inflammation, a different mechanism.
• In rare diseases like MPS I, Jupiter's JNS102 is targeting areas untreated by existing Enzyme Replacement Therapy (ERT) like Sanofi Genzyme's Aldurazyme (costing over $500,000 annually). Competitors like RegenexBio (gene therapy RGX-111) and Sigilon Therapeutics (SIG-005) are also developing advanced therapies, indicating a competitive landscape for orphan drugs.
• For MELAS Syndrome, Jupiter's JNS107 is in preclinical stages, aiming to increase mitochondrial biogenesis. Currently, no therapies are approved for MELAS in the US or EU. Competitors like Cyclerion Therapeutics (CY643 in Phase 1B) and Abliva AB (KL1333 in Phase II/III) are further along in clinical development, suggesting Jupiter is a laggard in this specific rare disease space.
• In the nutraceutical market, Nugevia competes with brands like ChromaDex (Tru-Niagen), Novos (NOVOS Core), Timelines (urolithin A), and Tally Health, as well as larger players like Nestle Health Science. Nugevia's use of JOTROL for enhanced bioavailability is a key differentiator, as many competitors also use advanced delivery systems (e.g., liposomal, micellar) to improve absorption of ingredients like resveratrol, NMN, and CoQ10.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any litigation the outcome of which, if determined adversely, would individually or taken together have a material adverse effect on its business, operating results, cash flows, or financial condition.
• In July 2022, Tiberend Strategic Advisors filed a summons for civil action against the company alleging non-payment of $130,400 under a services agreement. This was settled in March 2023 for a $150,000 convertible promissory note, which was fully repaid by December 2024.

Related Party Transactions

• The CEO, Christer Rosn, loaned the company working capital since inception. The outstanding balance of $146,432 as of December 31, 2024, was fully settled in 2025 by repaying $150,782 (principal and accrued interest).
• On April 29, 2024, the CEO exchanged 685,867 shares issued to a Note II holder for his related party notes totaling $266,667, which accrued interest at 3%.
• On March 15, 2024, a former executive forgave $100,000 of accrued compensation in exchange for 49,605 stock options and 7,500 restricted stock units, resulting in a $40,000 gain on forgiveness of accrued compensation.
• As of December 31, 2025 and 2024, $64,105 was due to a company wholly owned by the CFO, Saleem Elmasri, and is included in accrued compensation.
• The company entered into a Master Services Agreement with Titan Advisory Services LLC, wholly-owned by CFO Saleem Elmasri and his wife, on December 31, 2022. Titan provides CFO services for a monthly fee, initially $25,000, reduced to $5,000 from October 1, 2023, until December 4, 2024, then adjusted to $20,000 monthly. Mr. Elmasri was also issued an option to acquire 562,500 shares of common stock.
• Christer Rosn, CEO, is the father of Alexander Rosn, Chief Administrative Officer.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity raises (SEPA, convertible notes) and past issuances for services. The 'going concern' doubt and Nasdaq delisting risk pose substantial threats to investment value and liquidity. The fee-shifting provision in bylaws could discourage shareholder lawsuits.
• **Employees:** Executive officers experienced salary reductions in 2023-2024, which were later adjusted. Stock options and restricted stock units are part of compensation, aligning interests with company performance. The company's ability to attract and retain highly skilled personnel is crucial for R&D success.
• **Customers (Nugevia):** Benefit from new longevity and wellness products leveraging JOTROL technology. However, consumer skepticism about resveratrol's efficacy and potential product liability claims could impact trust and adoption.
• **Suppliers/Partners:** Aquanova AG is a critical partner for JOTROL technology, with license fees and potential milestone/royalty payments. Catalent Pharmaceutical Services is the sole manufacturer for JOTROL clinical supplies, making the company vulnerable to disruptions. Asian partners received significant equity for services, with risks if performance is inadequate.
• **Creditors:** The company's substantial indebtedness and 'going concern' doubt increase credit risk. The deferral of convertible note payments indicates financial strain.
• **Regulatory Bodies (FDA, Nasdaq):** The company is subject to strict regulatory oversight for drug development and dietary supplements. Non-compliance with Nasdaq listing rules could lead to delisting, while issues with FDA regulations could halt product development or commercialization.

Next Steps

• Initiate Phase IIa clinical trial for Parkinson's Disease (JNS115) in the second quarter of 2026, with initial results anticipated 12 months thereafter.
• Investigate other CNS indications, such as Mild Cognitive Impairment (MCI) and Alzheimer's disease, following the Parkinson's study.
• Submit a new grant application for the Phase II trial in MCI/early Alzheimer's disease after obtaining results from the Parkinson's Phase IIa study.
• Actively monitor compliance with Nasdaq continued listing requirements and consider available options, including a reverse stock split, to regain compliance by August 25, 2026.
• Continue business development activities in China, Malaysia, and Singapore, aiming to penetrate the Asian market through out-licensing deals.
• Market Nugevia products in the U.S. and internationally, with planned expansion to Europe, the Middle East, and Southeast Asia through regional partnerships.
• Repay convertible promissory notes to Yorkville, with monthly installment payments commencing April 1, 2026, and maturity on October 24, 2026.
• Address material weaknesses in internal control over financial reporting, specifically regarding segregation of duties and formal internal control environment.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, warranting a 'strong sell' recommendation. The company reported a substantial increase in net losses and negative cash flow in 2025, leading to an accumulated deficit of over $34 million. Crucially, both management and the independent auditor have expressed 'substantial doubt' about the company's ability to continue as a going concern. This fundamental uncertainty about survival, coupled with recent Nasdaq delisting notices for failing to meet minimum bid price and market value requirements, indicates severe financial distress and significant operational risks. While the company has ongoing clinical trials and a new consumer product line, these are early-stage and have not generated meaningful revenue to offset the escalating losses. The reliance on future capital raises, which may cause further dilution or be unavailable on favorable terms, exacerbates the precarious financial position. The non-refundable payments to strategic partners without performance guarantees also represent a notable risk. Given these severe financial and operational challenges, the stock carries an exceptionally high risk profile with a strong likelihood of further value erosion.

Keywords

Neurosciences, Pharmaceutical, Biotechnology, Resveratrol, JOTROL, Parkinson's Disease, Alzheimer's Disease, Rare Diseases, Nugevia, Nutraceuticals, Clinical Trials, SEC Filing, 10-K, Going Concern, Nasdaq, Equity Financing, Intellectual Property, Drug Development, Bioavailability, CNS Disorders, Mitochondrial Health, Longevity